Devil in the Tail: A Multi-Modal Framework for Drug-Drug Interaction Prediction in Long Tail Distinction

• URL: http://arxiv.org/abs/2410.12249v1
• Date: Wed, 16 Oct 2024 05:21:22 GMT
• Title: Devil in the Tail: A Multi-Modal Framework for Drug-Drug Interaction Prediction in Long Tail Distinction
• Authors: Liangwei Nathan Zheng, Chang George Dong, Wei Emma Zhang, Xin Chen, Lin Yue, Weitong Chen,
• Abstract summary: Drug-drug interaction (DDI) identification is a crucial aspect of pharmacology research. In this paper, a novel multi-modal deep learning-based framework, namely TFDM, is introduced to leverage multiple properties of a drug to achieve DDI classification. To tackle the challenge posed by the distribution skewness across categories, a novel loss function called Tailed Focal Loss is introduced.
• Score: 12.430490805111921
• License:
• Abstract: Drug-drug interaction (DDI) identification is a crucial aspect of pharmacology research. There are many DDI types (hundreds), and they are not evenly distributed with equal chance to occur. Some of the rarely occurred DDI types are often high risk and could be life-critical if overlooked, exemplifying the long-tailed distribution problem. Existing models falter against this distribution challenge and overlook the multi-faceted nature of drugs in DDI prediction. In this paper, a novel multi-modal deep learning-based framework, namely TFDM, is introduced to leverage multiple properties of a drug to achieve DDI classification. The proposed framework fuses multimodal features of drugs, including graph-based, molecular structure, Target and Enzyme, for DDI identification. To tackle the challenge posed by the distribution skewness across categories, a novel loss function called Tailed Focal Loss is introduced, aimed at further enhancing the model performance and address gradient vanishing problem of focal loss in extremely long-tailed dataset. Intensive experiments over 4 challenging long-tailed dataset demonstrate that the TFMD outperforms the most recent SOTA methods in long-tailed DDI classification tasks. The source code is released to reproduce our experiment results: https://github.com/IcurasLW/TFMD_Longtailed_DDI.git

Related papers

• Learning to Describe for Predicting Zero-shot Drug-Drug Interactions [54.172575323610175]
  Adverse drug-drug interactions can compromise the effectiveness of concurrent drug administration. Traditional computational methods for DDI prediction may fail to capture interactions for new drugs due to the lack of knowledge. We propose TextDDI with a language model-based DDI predictor and a reinforcement learning(RL)-based information selector.
  arXiv  Detail & Related papers  (2024-03-13T09:42:46Z)
• Accurate and interpretable drug-drug interaction prediction enabled by knowledge subgraph learning [39.66471292348325]
  We present KnowDDI, a graph neural network-based method that addresses the challenge of discovering potential drug-drug interactions. KnowDDI enhances drug representations by adaptively leveraging rich neighborhood information from large biomedical knowledge graphs. As an original open-source tool, KnowDDI can help detect possible interactions in a broad range of relevant interaction prediction tasks.
  arXiv  Detail & Related papers  (2023-11-25T15:44:28Z)
• DDI Prediction via Heterogeneous Graph Attention Networks [0.0]
  Polypharmacy is the use of multiple drugs together. Drug-drug interaction (DDI) is the activity that occurs when the impact of one drug changes when combined with another. We present a novel heterogeneous graph attention model, HAN-DDI, to predict drug-drug interactions.
  arXiv  Detail & Related papers  (2022-07-12T16:59:06Z)
• HyGNN: Drug-Drug Interaction Prediction via Hypergraph Neural Network [0.0]
  Drug-Drug Interactions (DDIs) may hamper the functionalities of drugs, and in the worst scenario, they may lead to adverse drug reactions (ADRs) This paper proposes a novel Hypergraph Neural Network (HyGNN) model based on only the SMILES string of drugs, available for any drug, for the DDI prediction problem. Our proposed HyGNN model effectively predicts DDIs and impressively outperforms the baselines with a maximum ROC-AUC and PR-AUC of 97.9% and 98.1%, respectively.
  arXiv  Detail & Related papers  (2022-06-25T22:48:27Z)
• SSM-DTA: Breaking the Barriers of Data Scarcity in Drug-Target Affinity Prediction [127.43571146741984]
  Drug-Target Affinity (DTA) is of vital importance in early-stage drug discovery. wet experiments remain the most reliable method, but they are time-consuming and resource-intensive. Existing methods have primarily focused on developing techniques based on the available DTA data, without adequately addressing the data scarcity issue. We present the SSM-DTA framework, which incorporates three simple yet highly effective strategies.
  arXiv  Detail & Related papers  (2022-06-20T14:53:25Z)
• Multi-View Substructure Learning for Drug-Drug Interaction Prediction [69.34322811160912]
  We propose a novel multi- view drug substructure network for DDI prediction (MSN-DDI) MSN-DDI learns chemical substructures from both the representations of the single drug (intra-view) and the drug pair (inter-view) simultaneously and utilizes the substructures to update the drug representation iteratively. Comprehensive evaluations demonstrate that MSN-DDI has almost solved DDI prediction for existing drugs by achieving a relatively improved accuracy of 19.32% and an over 99% accuracy under the transductive setting.
  arXiv  Detail & Related papers  (2022-03-28T05:44:29Z)
• Coupled and Uncoupled Dynamic Mode Decomposition in Multi-Compartmental Systems with Applications to Epidemiological and Additive Manufacturing Problems [58.720142291102135]
  We show that Dynamic Decomposition (DMD) may be a powerful tool when applied to nonlinear problems. In particular, we show interesting numerical applications to a continuous delayed-SIRD model for Covid-19.
  arXiv  Detail & Related papers  (2021-10-12T21:42:14Z)
• SDF-Bayes: Cautious Optimism in Safe Dose-Finding Clinical Trials with Drug Combinations and Heterogeneous Patient Groups [84.63561578944183]
  This paper proposes a novel Bayesian design, SDF-Bayes, for finding the maximum tolerated dose (MTD) of a drug in a clinical trial. Rather than the conventional principle of escalating or de-escalating the current dose of one drug, SDF-Bayes proceeds by cautious optimism. Extensive experiments based on both synthetic and real-world datasets demonstrate the advantages of SDF-Bayes over state of the art DC trial designs.
  arXiv  Detail & Related papers  (2021-01-26T18:59:26Z)
• AttentionDDI: Siamese Attention-based Deep Learning method for drug-drug interaction predictions [0.9176056742068811]
  Drug-drug interactions (DDIs) refer to processes triggered by the administration of two or more drugs leading to side effects beyond those observed when drugs are administered by themselves. Due to the massive number of possible drug pairs, it is nearly impossible to experimentally test all combinations and discover previously unobserved side effects. We propose a Siamese self-attention multi-modal neural network for DDI prediction that integrates multiple drug similarity measures.
  arXiv  Detail & Related papers  (2020-12-24T13:33:07Z)
• Two Step Joint Model for Drug Drug Interaction Extraction [82.49278654043577]
  Drug-Drug Interaction (DDI) Extraction from Drug Labels challenge of Text Analysis Conference (TAC) 2018. We propose a two step joint model to detect DDI and it's related mentions jointly. A sequence tagging system (CNN-GRU encoder-decoder) finds precipitants first and search its fine-grained Trigger and determine the DDI for each precipitant in the second step.
  arXiv  Detail & Related papers  (2020-08-28T15:30:08Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.